Bristol-Myers Squibb (NYSE: BMY) has posted profits from the latest quarter that missed analysts’ expectations.
The US pharma major did beat Wall Street estimates with its revenue from the third quarter, of $5.25 billion, which was a 7% rise on the same three months of 2016 and above the $5.19 billion that analysts expected.
Earnings for the latest quarter declined to $845 million, or $0.51 per share, from $1.2 billion, or $0.72 per share in the year-earlier period. Adjusted earnings-per-share were $0.75, below the Wall Street estimate of $0.77.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze